Blood markers in primary vs. secondary antiphospholipid syndrome
Part of Immune system & allergy clinical trials.
This study looks at three blood markers (MPV, PLR, and NLR) in people with antiphospholipid syndrome (APS) to see if they differ between primary APS (no other autoimmune disease) and secondary APS (with lupus or another autoimmune condition). It may help doctors better understand and manage APS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with antiphospholipid syndrome (APS) based on updated guidelines, meaning you have had blood clots or pregnancy complications and positive antibody tests (like aCL, anti-β2-glycoprotein I, or lupus anticoagulant) for at least 12 weeks.
- You do not currently have an infection or other inflammatory condition that is not caused by APS.
- You do not have a blood cancer (like leukemia) or other blood disorder.
- You have not had a recent blood transfusion or taken medications that change your platelet count, except for APS treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how platelet counts change over time in people with antiphospholipid syndrome (APS), a condition that can cause blood clots and pregnancy problems. It may help doctors better understand and manage low platelets in APS patients.
This trial looks at how people with primary or secondary antiphospholipid syndrome (a condition where the immune system wrongly increases blood clot risk) do over time. It aims to understand if one type has different outcomes, which could help guide better care.
This trial looks at people who have symptoms of antiphospholipid syndrome (APS) but test negative for the usual antibodies. It will compare these patients to those with positive antibody tests to better understand the condition and improve diagnosis and treatment.
This study looks at genetic (inherited) risk factors in people who have antiphospholipid antibodies and related symptoms. Your results may help researchers better predict who is at risk and improve care for antiphospholipid antibody syndrome.
This study looks at lab results and clinic information in people who have antiphospholipid antibodies. The goal is to better understand these antibody-positive conditions and what happens over time, which may help improve care.
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
Hear when a new Antiphospholipid Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.